EU medicine approvals

Bones and joints Medicines Approved in the EU (EMA)

Medicines the European Medicines Agency has recommended for use in the European Union on this topic.

Each number has its full source under its own list below.

Medicines authorised in the EU

161 medicines (authorised now). Newest first. Each links to its EMA page.

At the source

  • Denosumab Ascend

    Active substance: denosumab

    EMEA/H/C/006626

  • Tuyory

    EMEA/H/C/006416

  • Zandoriah

    Active substance: teriparatide

    EMEA/H/C/006688

  • Fubelv

    EMEA/H/C/006738

  • Gotenfia

    Active substance: golimumab

    EMEA/H/C/006621

  • Osqay

    Active substance: denosumab

    EMEA/H/C/006492

  • Degevma

    Active substance: denosumab

    EMEA/H/C/006239

  • Gobivaz

    Active substance: golimumab

    EMEA/H/C/006560

  • Xbonzy

    Active substance: denosumab

    EMEA/H/C/006722

  • Usgena

    Active substance: ustekinumab

    EMEA/H/C/006667

  • Kefdensis

    Active substance: denosumab

    EMEA/H/C/006490

  • Acvybra

    Active substance: denosumab

    EMEA/H/C/006734

  • Vysribli (previously Denosumab Intas)

    Active substance: denosumab

    EMEA/H/C/006797

  • Ponlimsi

    Active substance: denosumab

    EMEA/H/C/006238

  • Zvogra

    Active substance: denosumab

    EMEA/H/C/006552

Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.

Benchmarks on bones and joints

Countries side by side on public measures for this topic.

All benchmarks

Market reports on bones and joints

Search all
Digital Health

3D Printed Implants

Worldwide · 2024–2034

View report Medical Devices

3D-Printed Orthopedic Implants

Worldwide · 2024–2034

View report Pharmaceuticals

Autologous Matrix-induced Chondrogenesis

Worldwide · 2024–2034

View report Pharmaceuticals

Axial Spondyloarthritis (axSpA)

Worldwide · 2024–2034

View report OTC & Nutraceuticals

Bone & Joint Health Supplements

Worldwide · 2024–2034

View report Healthcare Services

Bone Cancer Diagnostic

Worldwide · 2024–2034

View report

From our blog

All stories

Bone and Joint Health: Supplements for an Ageing Population

1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence…

Read

Vitamin D: Deficiency, Testing and Supplements

Vitamin D is made in sunlight, yet low levels are common even in sunny countries. How much you need, and when…

Read

Collagen Supplements: Skin, Joints and Real Evidence

Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…

Read

EU medicine approvals on related topics

All topics

Acuitas market sizes and forecasts are only in our full reports. How we use public data.